For instance, 89Zr-Df-crefmirlimab, which shows strong affinity to CD8+ T-cells, has been used in clinical trials to identify the distribution of CD8+ T cells in the CNS of adults with MS and hence provide in-vivo imaging of the immune response, thereby enabling in vivo imaging of the adaptive immune response (NCT05849467). The gene discussed is CD8A; the disease is myeloid sarcoma.